CDMO Samsung Biologics bags $1.2B production contract, bringing total 2024 deal value to $3.3B+

With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one.

Samsung has locked down a $1.2 billion contract with an unnamed Asia-based pharmaceutical company that’s expected to run through December 2037.